Patents Represented by Attorney John W. Wallen

Find this attorney in the Justia Lawyer Directory

  • IRAK modified transgenic animals
    Patent number: 6166289
    Abstract: A transgenic animal with alterations in an IRAK gene is prepared by introduction of an altered IRAK gene into a host animal. The resulting transgenic animals do not produce functional IRAK molecules. Cells and cell lines derived from these animals also contain the altered IRAK gene.
    Type: Grant
    Filed: May 13, 1999
    Date of Patent: December 26, 2000
    Assignee: Ortho-McNeil Pharmacueticals
    Inventors: Crafford A. Harris, John J. Siekierka, Per A. Peterson, Wai-Ping Leung
  • PAR2 modified transgenic mice
    Patent number: 6077990
    Abstract: Transgenic mice with a non-functional proteinase activated receptor-2 (PAR2) gene are prepared by targeted disruption of the endogenous PAR2 gene. The resulting transgenic mice display a phenotype including a lack of a hypotensive response to administration of the peptide, SLIGRL, and a reduction in carrageenin-induced paw edema compared to wild type mice.
    Type: Grant
    Filed: August 11, 1998
    Date of Patent: June 20, 2000
    Assignee: Ortho-McNeil Pharmaceutical, Inc.
    Inventors: Wai-Ping Leung, Andrew Darrow, Patricia Andrade-Gordon
  • Cysteine-modified acidic fibroblast growth factor
    Patent number: 5223483
    Abstract: Mutant human acidic fibroblast growth factor proteins are recombinantly produced having replaced cysteine residues with amino acids incapable of disulfide bond formation. The recombinantly produced mutant human acidic fibroblast growth factor proteins have improved biological activity in the absence of heparin when compared to wild-type recombinant human acidic fibroblast growth factor.
    Type: Grant
    Filed: August 28, 1992
    Date of Patent: June 29, 1993
    Assignee: Merck & Co., Inc.
    Inventors: Kenneth A. Thomas, David L. Linemeyer